Cancer Genetics Appoints Renowned Biotech Entrepreneur Dr. Thomas F. Widmann to its Board of Directors
November 27 2017 - 8:00AM
Cancer Genetics, Inc. (Nasdaq:CGIX), a leader in enabling precision
medicine for oncology through molecular markers and diagnostics,
today announced the appointment of renowned biotech entrepreneur
Thomas F. Widmann, MD to the Company's Board of Directors.
“We have significantly enhanced our Board of
Directors with the appointment of Dr. Widmann. His extensive
clinical development and executive leadership experience across
multiple functions in the life sciences industry will be invaluable
for Cancer Genetics as we work to expand internationally and forge
new industry partnerships. In particular, Dr. Widmann’s success
co-founding and leading the international growth of Actelion
Pharmaceuticals will provide a strong guide for CGI. We look
forward to working closely with Dr. Widmann and gaining strategic
insights on optimizing our business growth and advancing our
portfolio as we continue establishing our company at the forefront
of precision oncology," said Panna Sharma, President and CEO of
Cancer Genetics Inc.
Dr. Thomas F. Widmann is a cardiologist and
seasoned life sciences entrepreneur with more than 25 years of
biotech experience, and also serves as a Venture Partner at
Wellington Partners in Germany. In 1997, he co-founded Actelion
Pharmaceuticals, Europe’s largest biopharmaceutical company. As
Actelion’s first Chief Executive Officer and Vice Chairman of the
Board, he established affiliates in North America, Europe, and
Asia. He was instrumental in Actelion’s highly successful IPO and
secondary offering, which created the foundation for Actelion’s
growth and profitability. Dr. Widmann has founded several other
successful companies, including Hesperion Ltd, an international
Contract Research Organization (CRO); Widmann Associates Ltd.; and
Auraglobe Ltd., both life-science advisory companies. Previously,
he spent nine years at Hoffmann-La Roche (HLR), Basel, leading the
international cardiovascular development department, where he
brought three cardiovascular drugs to the international markets. He
spent six years at the University of California at San Diego (UCSD)
as an assistant professor of Medicine. Dr. Widmann studied Medicine
and Computer Science at the Universities of Heidelberg and Paris,
and holds a Doctorate in Medicine from the University of
Heidelberg. He earned his specialization in cardiology at the
University of Geneva in Switzerland.
Dr. Widmann, commented, “Cancer Genetics is
rapidly evolving into a provider of actionable molecular
information to drive therapeutic decision-making and improve
patient care through personalized medicine. With its unique,
multi-dimensional clinical lab offerings and focus in molecular
testing for precision oncology, the company is well-positioned to
make a powerful impact on the biopharma space. I look forward to
working closely with management and my fellow Board members to
navigate and direct future clinical and corporate development
initiatives leading to its success.”
Additional members of Cancer Genetics’ board
include John Pappajohn (Non-executive Chairman), Edmund Cannon,
Raju S.K. Chaganti, Ph.D., Geoffrey Harris, Howard McLeod,
Pharm.D., Franklyn Prendergast, M.D., Ph.D., Panna Sharma (CEO and
President), and Michael J. Welsh, MD.
ABOUT CANCER GENETICS Cancer Genetics Inc. is a
leader in enabling precision medicine in oncology from bench to
bedside through the use of oncology biomarkers and molecular
testing. CGI is developing a global footprint with locations in the
US, India and China. We have established strong clinical research
collaborations with major cancer centers such as Memorial Sloan
Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of
Medicine at USC and the National Cancer Institute.
The Company offers a comprehensive range of laboratory services
that provide critical genomic and biomarker information. Its
state-of-the-art reference labs are CLIA-certified and
CAP-accredited in the US and have licensure from several states
including New York State.
For more information, please visit or follow CGI at:
Internet: www.cancergenetics.com
Twitter: @Cancer_Genetics
Facebook: www.facebook.com/CancerGenetics
Forward-Looking Statements: This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements
pertaining to Cancer Genetics Inc.’s future expectations constitute
forward-looking statements.
Any statements that are not historical fact (including, but not
limited to, statements that contain words such as “will,”
“believes,” “plans,” “anticipates,” “expects,” “estimates”) should
be considered to be forward-looking statements. Forward-looking
statements involve risks and uncertainties, including, without
limitation, risks inherent in the development and/or
commercialization of potential products, risks of cancellation of
customer contracts or discontinuance of trials, risks that
anticipated benefits from acquisitions will not be realized,
uncertainty in the results of clinical trials or regulatory
approvals, need and ability to obtain future capital, maintenance
of intellectual property rights and other risks discussed in the
Cancer Genetics, Inc. Form 10-K for the year ended December 31,
2016 and the Form 10-Q for the quarter ended September 30, 2017
along with other filings with the Securities and Exchange
Commission. These forward-looking statements speak only as of the
date hereof. Cancer Genetics, Inc. disclaims any obligation to
update these forward-looking statements.
ContactsMedia RelationsKirsten Thomas
508-280-6592kthomas@theruthgroup.com
Investor RelationsLee Roth / Robert Flamm646-536-7012 /
7017lroth@theruthgroup.com /
rflamm@theruthgroup.com
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Jul 2023 to Jul 2024